Beren pockets $300m to take Niemann-Pick disease therapy to market - Pharmaceutical Technology

If approved, Beren's adrabetadex would join Zevra Therapeutics’ Miplyffa and IntraBio’s Aqneursa on the I-NPC market. If approved, adrabetadex would be the third addition to the I-NPC treatment paradigm. Beren has secured up to $300m to support the potential launch of its rare lysosomal storage disease therapy, adrabetadex. Credit: Vector mall / Shutterstock.com. Beren Therapeutics has secured $300m in combined funding to support the potential commercial launch of its infantile-onset Niemann-Pick disease, type C (I-NPC) therapy, adrabetadex. Split into an Eisai-backed equity funding round worth $135m, as well as up to $165m worth of strategic financing from Hercules Capital, the…

Source: Pharmaceutical Technology